enVVeno Medical Corp (NVNO) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.80M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$4.06M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$4.88M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$7.05M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$3.80M | (m) | (m) | (m) | (m) | -$3.55M* | (m) | $2.08M | $1.72M | (m) |
| 2026-03-31 | Reported | (m) | -$4.06M | (m) | (m) | (m) | (m) | -$3.24M | (m) | $2.11M | $1.95M | (m) |
| 2025-09-30 | Reported | (m) | -$4.88M | (m) | (m) | (m) | $0.00* | -$4.39M* | (m) | $2.58M | $2.30M | (m) |
| 2025-06-30 | Reported | (m) | -$7.05M | (m) | (m) | (m) | (m) | -$3.71M* | (m) | $2.89M | $4.16M | (m) |
| 2025-03-31 | Reported | (m) | -$4.95M | (m) | (m) | (m) | (m) | -$4.02M | (m) | $2.56M | $2.40M | (m) |
| 2024-09-30 | Reported | (m) | -$6.17M | (m) | (m) | (m) | $9.00K* | -$4.28M* | (m) | $2.86M | $3.31M | (m) |
| 2024-06-30 | Reported | (m) | -$5.45M | (m) | (m) | (m) | $14.00K* | -$3.91M* | (m) | $2.83M | $2.63M | (m) |
| 2024-03-31 | Reported | (m) | -$5.50M | (m) | (m) | (m) | $10.00K | -$3.55M | (m) | $3.05M | $2.45M | (m) |
| 2023-09-30 | Reported | (m) | -$5.35M | (m) | (m) | (m) | $3.00K* | -$4.21M* | (m) | $2.80M | $2.55M | (m) |
| 2023-06-30 | Reported | (m) | -$6.81M | (m) | (m) | (m) | $21.00K* | -$4.56M* | (m) | $4.21M | $2.60M | (m) |
| 2023-03-31 | Reported | (m) | -$6.80M | (m) | (m) | (m) | $5.00K | -$5.11M | (m) | $3.60M | $3.20M | (m) |
| 2022-09-30 | Reported | (m) | -$6.15M | (m) | (m) | (m) | $14.00K* | -$4.48M* | (m) | $2.49M | $3.66M | (m) |
| 2022-06-30 | Reported | (m) | -$6.99M | (m) | (m) | (m) | $23.00K* | -$3.96M* | (m) | $3.07M | $3.91M | (m) |
| 2022-03-31 | Reported | (m) | -$5.33M | (m) | (m) | (m) | $69.00K | -$3.32M | (m) | $1.55M | $3.78M | (m) |
| 2021-09-30 | Reported | (m) | -$2.71M | (m) | (m) | (m) | $152.00K* | -$2.23M* | (m) | $1.23M | $1.48M | (m) |
| 2021-06-30 | Reported | (m) | -$2.39M | (m) | (m) | (m) | $127.00K* | -$2.67M* | (m) | $1.09M | $1.30M | (m) |
| 2021-03-31 | Reported | (m) | -$2.81M | (m) | (m) | (m) | $24.00K | -$3.84M | (m) | $1.63M | $1.18M | (m) |
| 2020-09-30 | Reported | (m) | -$1.92M | (m) | (m) | (m) | $24.96K* | -$2.59M* | (m) | $758.20K | $1.16M | (m) |
| 2020-06-30 | Reported | (m) | -$1.55M | (m) | (m) | (m) | $122.47K* | -$1.32M* | (m) | $706.17K | $839.74K | (m) |
| 2020-03-31 | Reported | (m) | -$1.51M | (m) | (m) | (m) | $5.31K | -$1.15M | (m) | $510.62K | $997.90K | (m) |
| 2019-09-30 | Reported | (m) | -$1.83M | (m) | $0.00* | (m) | $171.90K* | -$1.35M* | (m) | $676.97K | $1.16M | (m) |
| 2019-06-30 | Reported | (m) | -$1.96M | (m) | $0.00* | (m) | $177.23K* | -$1.43M* | (m) | $428.31K | $1.53M | (m) |
| 2019-03-31 | Reported | (m) | -$1.58M | (m) | $31.24K | (m) | $1.80K | -$1.49M | (m) | $313.01K | $1.30M | (m) |
| 2018-09-30 | Reported | (m) | -$1.49M | (m) | $41.66K | (m) | (m) | -$1.74M* | (m) | $424.60K | $1.10M | (m) |
| 2018-06-30 | Reported | (m) | -$3.11M | (m) | $83.36K | (m) | (m) | -$1.54M* | (m) | $280.42K | $2.91M | (m) |
| 2018-03-31 | Reported | (m) | -$1.46M | (m) | $31.07K | (m) | (m) | -$1.63M | (m) | $240.49K | $1.25M | (m) |
| 2017-09-30 | Reported | (m) | -$1.81M | (m) | $27.88K | (m) | $0.00* | -$1.21M* | (m) | $43.07K | $1.66M | (m) |
| 2017-06-30 | Reported | (m) | -$1.23M | (m) | $38.80K | (m) | (m) | (m) | (m) | $184.92K | $1.09M | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$20.90M | (m) | (m) | (m) | $5.00K | -$15.57M | (m) | $9.98M | $10.92M | (m) |
| 2024-12-31 | Reported | (m) | -$23.83M | (m) | (m) | (m) | $37.00K | -$16.84M | (m) | $12.25M | $11.58M | (m) |
| 2023-12-31 | Reported | (m) | -$25.24M | (m) | (m) | (m) | $33.00K | -$18.86M | (m) | $13.58M | $11.65M | (m) |
| 2022-12-31 | Reported | (m) | -$24.93M | (m) | (m) | (m) | $115.00K | -$15.62M | (m) | $9.91M | $15.02M | (m) |
| 2021-12-31 | Reported | (m) | -$16.89M | (m) | (m) | (m) | $368.00K | -$11.85M | (m) | $5.73M | $11.16M | (m) |
| 2020-12-31 | Reported | (m) | -$9.14M | (m) | (m) | (m) | $180.29K | -$7.68M | (m) | $4.25M | $4.88M | (m) |
| 2019-12-31 | Reported | (m) | -$7.68M | (m) | $31.24K | (m) | $363.89K | -$5.90M | (m) | $2.21M | $4.91M | (m) |
| 2018-12-31 | Reported | (m) | -$7.85M | (m) | $186.55K | (m) | $12.42K | -$6.36M | (m) | $1.24M | $6.48M | (m) |
| 2017-12-31 | Reported | (m) | -$6.10M | (m) | $422.11K | (m) | $10.94K | -$4.20M | (m) | $649.74K | $5.46M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |